



RECEIVED
JAN 07 2003
TECH CENTER 1600/2900

REMARKS

Applicants in their prior Amendment of claim 4 inadvertently deleted the definition of R¹⁵. This Amendment reinserts this definition and is not new matter.

Favorable consideration and allowance of claims 1-19 and 25-31 is respectfully requested.

If any additional fees are incurred as a result of the filing of this paper, authorization is given to charge deposit account number 23-0785.

Respectfully submitted,

By: Martin L. Katz
Martin L. Katz (Reg. No. 25,011)
Attorney for Applicant

WOOD, PHILLIPS, KATZ, CLARK & MORTIMER
500 MADISON STREET, SUITE 3800
CHICAGO, IL 60661
(312) 876-1800

CERTIFICATE OF MAILING

I hereby certify that this Supplemental Amendment is being deposited with the U.S. Postal Service via First Class Mail to: Commissioner for Patents, Washington, DC 20231 on December 31, 2002.


A handwritten signature consisting of stylized initials "K" and "A" followed by the name "Kim Annel" written below it.

RECEIVED
JAN 07 2003
USPTO 1600/2900

MARKED UP VERSION OF CLAIMS

Please amend claim 4 as follows:

4. (twice amended) A compound of the structure



wherein Y, at each occurrence, is independently selected from the group consisting of C(O), N, CR¹, C(R²)(R³), NR⁵ and CH;

q is an integer of from 3 to 6;

T is (CH₂)_b wherein b is an integer of 0 to 2;

L is (CH₂)_n wherein n is an integer of 0 or 1;

W is selected from the group consisting of C and CR¹⁵;

B is H or alkyl;

R¹ at each occurrence is independently selected from the group consisting of

hydrogen, halogen, alkyl, alkoxy, -CF₃, -NH₂, -OH, NHC(O)N(C₁-C₃ alkyl), -NHSO₂(C₁-C₃ alkyl), alkylamino, di(C₁-C₃ alkyl)amino, cycloalkyl, aryl, arylamino, heterocyclyl and sulfonamido;

R¹ and R³ are hydrogen;

R⁴ is selected from the group consisting of

hydrogen, alkyl, aryl, biaryl, heterocyclyl, alkylaryl, aralkyl, heterocyclalkyl and alkylheterocyclyl;

R⁵ at each occurrence is independently selected from the group consisting of alkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclalkyl, heterocyclyl and aryloxyalkyl;

R⁶ and R⁷ are independently hydrogen or alkyl;

R^9 and R^{10} are independently selected from the group consisting of
hydrogen, alkyl and halogen; and

R^{15} is hydrogen;

wherein B , R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^9 , R^{10} and R^{15} are unsubstituted or
substituted with at least one electron donating or electron withdrawing
group;

and wherein when at least one Y is CR^1 , R^1 and R^6 taken together
may form a ring;

or a pharmaceutically acceptable salt thereof.